Clinical Trials Logo

Advanced Pancreatic Cancer clinical trials

View clinical trials related to Advanced Pancreatic Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04796948 Active, not recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Start date: April 8, 2021
Phase: Phase 1
Study type: Interventional

To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy

NCT ID: NCT04469556 Active, not recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma Signature Stratification for Treatment

PASS-01
Start date: October 14, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, and drug testing sensitivity and other biomarkers.

NCT ID: NCT04137536 Active, not recruiting - Pancreatic Cancer Clinical Trials

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Start date: October 17, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.

NCT ID: NCT04104672 Active, not recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

ARC-8
Start date: November 6, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

NCT ID: NCT02124317 Active, not recruiting - Clinical trials for Advanced Pancreatic Cancer

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer

NAPSPAC
Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus S-1 as first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma (PDA).

NCT ID: NCT01885884 Active, not recruiting - Clinical trials for Advanced Pancreatic Cancer

Supportive Care Intervention-Pancreas

SCI-P
Start date: July 2013
Phase: N/A
Study type: Interventional

This is a pilot, randomized controlled trial of an embedded collaborative model of supportive care designed to improve quality of life and decrease use of unwanted healthcare services at the end of life for patients with advanced pancreatic cancer. We will enroll 30 patients who are receiving treatment at the Hillman Cancer Center for recently diagnosed, locally advanced or metastatic pancreatic adenocarcinoma, as well as their accompanying caregivers and providers. Patients will be randomized to receive either the supportive care intervention or usual care. The purpose of this study is to refine an embedded collaborative model of supportive care and to develop protocols for recruitment, randomization, and longitudinal data collection.